About us
Advancing bioelectronic medicine to restore balance, relieve pain, correct dysregulated inflammation and empower the body’s natural healing systems.
Cymbathera AB is a bioelectronic medicine company founded by leading scientists from Karolinska Institutet and the Feinstein Institute for Medical Research Northwell Health, including professors Ulf Andersson and Kevin Tracey, pioneers in the scientific exploration of the inflammatory reflex. Built on decades of neuroimmunology research, the company translates fundamental neuroscience into non-invasive technologies designed to help relieve pain and address chronic inflammation by supporting the body’s natural regulatory systems. Our work focuses on vagus nerve stimulation as a drug-free, science-based approach to pain relief and nervous system balance. By combining rigorous clinical research with human-centered medical device design, Cymbathera AB aims to make bioelectronic medicine accessible beyond the laboratory and into everyday life.
Vision & Mission
Our work is driven by a clear purpose: to translate neuroscience into simple health solutions that help the body restore balance and support long-term well-being.
Mission
Our mission is to transform decades of neuroimmunology research into safe, non-invasive technologies that support the body’s natural regulatory systems and make evidence-based care accessible anytime, anywhere.
Vision
Our vision is a future where chronic inflammation and nervous system imbalance are addressed through science-based neuromodulation, empowering people worldwide to live healthier lives with greater resilience, balance, and control over their health.
Company Founders
Ulf Andersson
Prof. of pediatric rheumatology at Karolinska Institutet. Worked at Karolinska for five decades as a clinician and a basic scientist focusing on inflammation. Co-discoverer of HMGB1 as the prototype alarmin molecule. Honorary doctor at Hofstra University in New York. Highly Cited Clarivate Researcher Web of Science awards.
Göran Brorsson
35+ yrs managerial experience in SME and big corporations in the Nordics, Europe, US, and Asia. Key leadership roles in operations of medical device products. Cross-cultural knowledge and background in management, global business development strategies and corporate transactions. Since 2015 independent advisor to MedTech and Life Science companies.
Kevin Tracey
President and CEO of the Feinstein Institutes at Northwell Health, and Professor of Neurosurgery and Molecular Medicine at Zucker School of Medicine at Hofstra-Northwell. His numerous awards and honors include an Honorary Doctorate at Karolinska Institutet and named to the 2026 TIME100 health list in the Innovator category for his work on bioelectronic medicine. Internationally recognized leader in the scientific fields of inflammation and bioelectronic medicine. Discoverer of the cholinergic anti-inflammatory pathway (the inflammatory reflex) and pioneer of anti-TNF monoclonal antibody therapy. Inventor on 75 U.S. patents and author of more than 400 scientific publications.
Jan Andersson
Professor of infectious diseases at Karolinska Institutet. Previous Deputy President of the Karolinska Institutet and Research Director of Region Stockholm. The Royal Institute of Technology's Gold Medal award of Innovation and Development in 2021 and the Karolinska Institutet:s Large Silver medal for contribution in science in 2022.
Anette Sjögren
30+ yrs of experience in the medical device and pharma industry as QA (Quality Assurance), RA (Regulatory Affairs), QP (Qualified Person) and expertise in the fields of clinical affairs, toxicology and biocompatibility. Member of the Swedish (TK355) and the International Technical (TC210) committees since 2010.
Career
We are always interested in meeting talented people who share our vision of reshaping inflammatory care through science and technology. If you want to be part of a purpose-driven, research-focused team, we invite you to get in touch.
